Compounds > 4-methyl-N-(pyridin-4-ylmethyl)benzenesulfonamide
Page last updated: 2024-11-09

4-methyl-N-(pyridin-4-ylmethyl)benzenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID651192
CHEMBL ID1598827
CHEBI ID121421

Synonyms (23)

Synonym
BAS 03585856
4-methyl-n-pyridin-4-ylmethyl-benzenesulfonamide
OPREA1_008160
smr000012434
MLS000072288 ,
CHEBI:121421
4-methyl-n-(pyridin-4-ylmethyl)benzenesulfonamide
AKOS003240658
STK792431
HMS2166A24
HMS3322L21
CHEMBL1598827
4-methyl-n-(4-pyridylmethyl)benzenesulfonamide
cid_651192
bdbm39083
CS-004/03994045
4-methyl-n-(4-pyridinylmethyl)benzenesulfonamide
XKDJGAPHTFVILP-UHFFFAOYSA-N
SR-01000361614-1
sr-01000361614
Q27209962
4-methyl-n-[(pyridin-4-yl)methyl]benzene-1-sulfonamide
4-methyl-n-(pyridin-4-yl-methyl)benzenesulfonamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.00000.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency4.77550.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency1.63600.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency3.88600.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency7.07950.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency2.51190.00018.4406100.0000AID720580
hepatitis C virus polyproteinPotency2.22800.444510.437124.9988AID720575
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.47460.00419.984825.9290AID504444; AID720524
huntingtin isoform 2Homo sapiens (human)Potency3.54810.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency7.41770.00798.23321,122.0200AID2546; AID2762; AID2763
gemininHomo sapiens (human)Potency0.29760.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency5.01190.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
muscle contractionGalanin receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayGalanin receptor type 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayGalanin receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGalanin receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGalanin receptor type 2Homo sapiens (human)
learning or memoryGalanin receptor type 2Homo sapiens (human)
feeding behaviorGalanin receptor type 2Homo sapiens (human)
neuron projection developmentGalanin receptor type 2Homo sapiens (human)
inositol phosphate metabolic processGalanin receptor type 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGalanin receptor type 2Homo sapiens (human)
phosphatidylinositol metabolic processGalanin receptor type 2Homo sapiens (human)
galanin-activated signaling pathwayGalanin receptor type 2Homo sapiens (human)
positive regulation of large conductance calcium-activated potassium channel activityGalanin receptor type 2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayGalanin receptor type 2Homo sapiens (human)
neuropeptide signaling pathwayGalanin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
galanin receptor activityGalanin receptor type 2Homo sapiens (human)
protein bindingGalanin receptor type 2Homo sapiens (human)
peptide hormone bindingGalanin receptor type 2Homo sapiens (human)
neuropeptide bindingGalanin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneGalanin receptor type 2Homo sapiens (human)
ciliumGalanin receptor type 2Homo sapiens (human)
membraneGalanin receptor type 2Homo sapiens (human)
plasma membraneGalanin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510